110 related articles for article (PubMed ID: 15663292)
1. Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma.
Abbara C; Rouchon C; Hosten B; Farinotti R; Bonhomme-Faivre L
Drug Metabol Drug Interact; 2004; 20(4):219-31. PubMed ID: 15663292
[TBL] [Abstract][Full Text] [Related]
2. Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice.
Hosten B; Abbara C; Petit B; Dauvin A; Bourasset F; Farinotti R; Gonin P; Bonhomme-Faivre L
Drug Metab Dispos; 2008 Aug; 36(8):1729-35. PubMed ID: 18508881
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice.
Bonhomme-Faivre L; Pelloquin A; Tardivel S; Urien S; Mathieu MC; Castagne V; Lacour B; Farinotti R
Anticancer Drugs; 2002 Jan; 13(1):51-7. PubMed ID: 11914641
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma.
Hosten B; Challuau D; Gil S; Bouquet C; Marion S; Perricaudet M; Di Palma M; Farinotti R; Bonhomme-Faivre L
Anticancer Drugs; 2006 Feb; 17(2):195-9. PubMed ID: 16428938
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
Jamois C; Comets E; Mentré F; Marion S; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2005 Jan; 55(1):61-71. PubMed ID: 15378273
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
8. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
Lee CK; Choi JS
Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
[TBL] [Abstract][Full Text] [Related]
9. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
Varma MV; Panchagnula R
Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice.
Hosten B; Abbara C; Cibert M; Petit B; Farinotti R; Gonin P; Bonhomme-Faivre L
Anticancer Drugs; 2010 Feb; 21(2):193-201. PubMed ID: 20016370
[TBL] [Abstract][Full Text] [Related]
11. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
Choi BC; Choi JS; Han HK
Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758
[TBL] [Abstract][Full Text] [Related]
12. Enhanced bioavailability of paclitaxel by bamboo concentrate administration.
Kang KW; Choi JS
Arch Pharm Res; 2005 Apr; 28(4):469-75. PubMed ID: 15918522
[TBL] [Abstract][Full Text] [Related]
13. Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo.
Yang LQ; Wang B; Gan H; Fu ST; Zhu XX; Wu ZN; Zhan DW; Gu RL; Dou GF; Meng ZY
Biopharm Drug Dispos; 2012 Nov; 33(8):425-36. PubMed ID: 22898996
[TBL] [Abstract][Full Text] [Related]
14. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
Park JH; Park JH; Hur HJ; Woo JS; Lee HJ
Eur J Pharm Sci; 2012 Feb; 45(3):296-301. PubMed ID: 22172604
[TBL] [Abstract][Full Text] [Related]
15. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats.
Li X; Choi JS
Int J Pharm; 2007 Jun; 337(1-2):188-93. PubMed ID: 17267149
[TBL] [Abstract][Full Text] [Related]
16. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice.
Castagne V; Bonhomme-Faivre L; Urien S; Ben Reguiga M; Soursac M; Gimenez F; Farinotti R
Drug Metab Dispos; 2004 Feb; 32(2):168-71. PubMed ID: 14744937
[TBL] [Abstract][Full Text] [Related]
17. [Mucopenetrating nanoparticles: vehicles for the oral administration of paclitaxel].
Zabaleta V; Calleja P; Espuelas S; Corrales L; Pío R; Agüeros M; Irache JM
Ann Pharm Fr; 2013 Mar; 71(2):109-18. PubMed ID: 23537412
[TBL] [Abstract][Full Text] [Related]
18. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles.
Mo R; Jin X; Li N; Ju C; Sun M; Zhang C; Ping Q
Biomaterials; 2011 Jul; 32(20):4609-20. PubMed ID: 21440934
[TBL] [Abstract][Full Text] [Related]
19. Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel.
Lee K; Chae SW; Xia Y; Kim NH; Kim HJ; Rhie S; Lee HJ
Eur J Pharmacol; 2014 Jan; 723():381-8. PubMed ID: 24252806
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.
Bardelmeijer HA; Ouwehand M; Beijnen JH; Schellens JH; van Tellingen O
Invest New Drugs; 2004 Aug; 22(3):219-29. PubMed ID: 15122069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
